

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 199932025 B2**
(10) Patent No. **748751**

(54) Title
The use of isolated domains of type IV collagen to modify cell and tissue interactions

(51)⁶ International Patent Classification(s)
A61K 038/39 C07K 014/78

(21) Application No: 199932025 (22) Application Date: 1999 .03 .26

(87) WIPO No: W099/49885

(30) Priority Data

(31) Number	(32) Date	(33) Country
60/079783	1998 .03 .27	US
60/106170	1998 .10 .29	US

(43) Publication Date : 1999 .10 .18
(43) Publication Journal Date : 1999 .12 .16
(44) Accepted Journal Date : 2002 .06 .13

(71) Applicant(s)
University of Kansas Medical Center

(72) Inventor(s)
Billy G. Hudson; Michael P. Sarras Jr.

(74) Agent/Attorney
SPRUSON and FERGUSON,GPO Box 3898,SYDNEY NSW 2001

(56) Related Art
JING HAN ET AL J. BIOL CHEM. V272(33) AUG 1997 PP20395-401
US 5691182

32025/99



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/39 // C07K 14/78		A2	(11) International Publication Number: WO 99/49885
			(43) International Publication Date: 7 October 1999 (07.10.99)
(21) International Application Number: PCT/US99/06445		(81) Designated States: AU, CA, JP, MX, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 26 March 1999 (26.03.99)			
(30) Priority Data: 60/079,783 27 March 1998 (27.03.98) US 60/106,170 29 October 1998 (29.10.98) US		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicant: UNIVERSITY OF KANSAS MEDICAL CENTER [US/US]; 3901 Rainbow Boulevard, Kansas City, KS 66160 (US).			
(72) Inventors: HUDSON, Billy, G.; Box 420, Omaha Park, AR 72662 (US). SARRAS, Michael, P., Jr.; 10820 Countryside Drive, Kansas City, KS 66103 (US).			
(74) Agent: HARPER, David, S.; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).			
IP AUSTRALIA 18 OCT 1999 RECEIVED			
(54) Title: THE USE OF ISOLATED DOMAINS OF TYPE IV COLLAGEN TO MODIFY CELL AND TISSUE INTERACTIONS			
(57) Abstract			
The instant invention provides methods and kits for inhibiting angiogenesis, tumor growth and metastasis, and endothelial cell interactions with the extracellular matrix, involving contacting the tumor or animal tissue with at least one isolated type IV collagen NC1 α chain monomer. In a specific embodiment of the invention, the isolated domain of type IV collagen comprises the NC1 (α1), (α2), (α3), or (α6) chain monomer, or protein constructs having substantially the same structure as the NC1 (α1), (α2), (α3), or (α6) chain monomer.			

The Use of Isolated Domains of Type IV Collagen To Modify Cell And Tissue Interactions

Field of the Invention

This invention relates to methods and kits for inhibiting angiogenesis, tumor growth
5 and metastasis, and endothelial cell interactions with the extracellular matrix.

Background In The Invention

Angiogenesis, the process of formation of new blood vessels, plays an important
role in physiological processes such as embryonic and postnatal development as well as in
wound repair. Formation of blood vessels can also be induced by pathological processes
10 involving inflammation (e.g., diabetic retinopathy and arthritis) or neoplasia (e.g., cancer)
(Folkman, 1985, Perspect, Biol. Med., 29, 10). Neovascularization is regulated by
angiogenic growth factors secreted by tumor or normal cells as well as the composition of
the extracellular matrix and by the activity of endothelial enzymes (Nicosia and Ottinetti,
1990, Lab. Invest., 63, 115).

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175

During the initial stages of angiogenesis, endothelial cell sprouts appear through gaps in the basement membrane of pre-existing blood vessels (Nicosia and Ottinetti, 1990, *supra*; Schoefl, 1963, Virehous Arch, Pathol. Anat. 337, 97-141; Ausprunk and Folkman, 1977, Microvasc. Res. 14, 53-65; Paku and Paweletz, 1991, Lab. Invest. 63, 334-346). As
5 new vessels form, their basement membrane undergoes complex structural and compositional changes that are believed to affect the angiogenic response (Nicosia, et. al., 1994, Exp. Biology, 164, 197-206). Early planar culture models have shown that basement membrane molecules modulate the attachment, migration and proliferation and organizational behavior of endothelial cells (Nicosia, et. al., 1994, *supra*). More recent
10 studies with three-dimensional aortic culture models that more closely simulate angiogenic conditions during wound healing in vivo suggest that basement membrane is a dynamic regulator of angiogenesis whose function varies according to its molecular components (Nicosia, 1994, *supra*).

A common feature of all solid tumor growth is the requirement for a blood supply.
15 Therefore, numerous laboratories have focused on developing anti-angiogenic compounds based on growth factors and their receptors. While this approach has led to some success, the number of growth factors known to play a role an angiogenesis is large. Therefore, the possibility exists that growth factor antagonists may have only limited use in treating cancer since tumors and associated inflammatory cells likely produce a wide variety of
20 factors that can induce angiogenesis.

In this regard, a strategy that targets a common feature of angiogenesis, such as endothelial cell adhesion to the extracellular matrix (ECM), might be expected to have a profound physiological impact on tumor growth in humans. This notion is supported by the fact that antagonists of specific ECM cell adhesion receptors such as $\alpha v\beta 3$ and $\alpha v\beta 5$

integrins can block angiogenesis. Furthermore, the $\alpha v\beta 3$ integrin is expressed most prominently on cytokine -activated endothelial and smooth muscle cells and has been shown to be required for angiogenesis. (Varner et al., Cell Adhesion and Communication 3:367-374 (1995); Brooks et al., Science 264:569-571 (1994)). Based on these findings, a
5 potentially powerful new approach to anti-angiogenic therapy might be to specifically target critical regulatory domains within distinct ECM components.

The basement membrane (basal lamina) is a sheet-like extracellular matrix (ECM), which is a basic component of all tissues. The basal lamina provides for the compartmentalization of tissues, and acts as a filter for substances traveling between tissue
10 compartments. Typically the basal lamina is found closely associated with an epithelium or endothelium in all tissues of an animal including blood vessels and capillaries. The basal lamina components are secreted by cells and then self assemble to form an intricate extra-cellular network. The formation of biologically active basal lamina is important to the development and differentiation of the associated cells.

15 Type IV collagen has been shown to be a major structural component of basement membranes. The protomeric form of type IV collagen is formed as a heterotrimer made up from a number of different subunit chains called $\alpha 1(IV)$ through $\alpha 6(IV)$. Up to now, six genetically distinct α -chains belonging to two classes with extensive homology have been identified, and their relative abundance has been demonstrated to be tissue specific.
20 The type IV collagen heterotrimer is characterized by three distinct structural domains: the non-collagenous (NC1) domain at the carboxyl terminus; the triple helical collagenous domain in the middle region; and the 7S collagenous domain at the amino terminus. (Martin, et. al., 1988, Adv. Protein Chem. 39:1-50; Gunwar, et. al. 1991, J. Biol. Chem. 266:14088-14094).

The capability of expression of recombinant α (IV) NC1 domains provides the opportunity to study the effect of specific domains on many biological processes, such as angiogenesis, tumor metastasis, cell binding to basement membranes, and assembly of Type IV collagen molecules.

Summary of the Invention

According to a first aspect, the present invention consists in a method for inhibiting angiogenesis in an animal tissue comprising contacting the tumor or animal tissue with an amount effective to inhibit angiogenesis of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of α 2, α 3, and α 6 NC1 chain monomers.

According to a second aspect, the present invention consists in a method for inhibiting tumor metastasis in tissue comprising contacting the tumor or tissue with an amount effective to inhibit tumor metastasis of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of α 2, α 3, and α 6 NC1 chain monomers.

According to a third aspect, the present invention consists in a method for inhibiting tumor growth in tissue comprising contacting the tumor or tissue with an amount effective to inhibit tumor growth of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of α 2, and α 6 NC1 chain monomers.

According to a fourth aspect, the present invention consists in a kit when used for practicing the method of the first aspect comprising:

- a. an amount effective to inhibit angiogenesis in an animal tissue of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of α 2, α 3, and α 6 NC1 chain monomers, and
- b. instructions for using the amount effective of isolated NC1 α chain monomers of type IV collagen to inhibit angiogenesis in an animal tissue.

According to a fifth aspect, the present invention consists in a kit when used for practicing the method of the second aspect comprising:

- a. an amount effective to inhibit tumor metastasis in tissue of an isolated domain of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of α 2, α 3, and α 6 NC1 chain monomers, and



b. instructions for using the amount effective of isolated NC1 α chain monomers of type IV collagen to inhibit tumor metastasis in an animal tissue.

According to a sixth aspect, the present invention consists in a kit when used for practicing the method of the third aspect comprising:

5 a. an amount effective to inhibit tumor growth in tissue of an isolated domain of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, and $\alpha 6$ NC1 chain monomers, and

10 b. instructions for using the amount effective of isolated NC1 α chain monomers of type IV collagen to inhibit tumor growth in an animal tissue.

According to a seventh aspect, the present invention consists in a method for inhibiting endothelial cell interaction with the extracellular matrix in an animal tissue comprising contacting the tumor or animal tissue with an amount effective to inhibit endothelial cell interaction with the extracellular matrix of a polypeptide composition
15 comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers.

According to an eighth aspect, the present invention consists in a kit when used for practicing the method of the seventh aspect comprising:

20 a. an amount effective to inhibit endothelial cell interaction with the extracellular matrix in an animal tissue of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers, and

25 b. instructions for using the amount effective of isolated NC1 α chain monomers of type IV collagen to inhibit endothelial cell interaction with the extracellular matrix in an animal tissue.

According to a ninth aspect, the present invention consists in a method for treating an angiogenesis-mediated disease or condition in a mammal, comprising administering to a mammal with an angiogenesis-mediated disease or condition an amount effective to inhibit angiogenesis of a polypeptide composition comprising one or more isolated NC1 α
30 chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers.

According to a tenth aspect, the present invention consists in a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers when used for inhibiting angiogenesis in an animal tissue.



According to an eleventh aspect, the present invention consists in a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers when used for inhibiting tumor metastasis in tissue.

5 According to a twelfth aspect, the present invention consists in a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, and $\alpha 6$ NC1 chain monomers when used for inhibiting tumor growth in tissue.

According to a thirteenth aspect, the present invention consists in a polypeptide
10 composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers when used for inhibiting endothelial cell interaction with the extracellular matrix in an animal tissue.

According to a fourteenth aspect, the present invention consists in a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen
15 selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers when used for treating an angiogenesis-mediated disease or condition in a mammal.

According to a fifteenth aspect, the present invention consists in use of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers in
20 the manufacture of a medicament for inhibiting angiogenesis in an animal tissue.

According to a sixteenth aspect, the present invention consists in use of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers in the manufacture of a medicament for inhibiting tumor metastasis in tissue.

25 According to a seventeenth aspect, the present invention consists in use of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, and $\alpha 6$ NC1 chain monomers in the manufacture of a medicament for inhibiting tumor growth in tissue.

According to an eighteenth aspect, the present invention consists in use of a
30 polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers in the manufacture of a medicament for inhibiting endothelial cell interaction with the extracellular matrix in an animal tissue.



According to a nineteenth aspect, the present invention consists in use of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers in the manufacture of a medicament for treating an angiogenesis-mediated disease or condition in a mammal.

There is disclosed methods and kits for inhibiting angiogenesis, tumor growth and metastasis, and endothelial cell interaction with the extracellular matrix, each method comprising contacting the tumor or animal tissue with one or more isolated type IV collagen NC1 α chain monomer selected from the group consisting of α chain monomer selected from the group consisting of $\alpha 1$, $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers.

Brief Description Of The Drawings

Figure 1 illustrates the effects of NC1 (Hexamer) and 7S domains of Type IV collagen at a 50 μ g/ml concentration on angiogenesis from mouse thoracic aorta organ cultures.

Figure 2 illustrates the effects of 7S domain of Type IV collagen on angiogenesis from mouse thoracic aorta organ cultures. The domain concentrations employed in this experiment were 0 μ g/ml (control); 0.5 μ g/ml; 5 μ g/ml and 50 μ g/ml.

Figure 3 illustrates the effects of NC1 (Hexamer) domain of Type IV collagen on angiogenesis from mouse thoracic aorta organ cultures. The domain concentrations employed in this experiment were 0 μ g/ml (control); 5 μ g/ml and 50 μ g/ml.

Figure 4 are photographs of mouse thoracic aorta segments embedded in Matrigel (EHS basement membrane matrix, Collaborative Biomedical Products, Bedford, MA) at 5 days of culture. Control specimen (0 μ g/ml of NC1 (Hexamer) and 7S domains) exhibited



growth of microvessels from the cultured tissue into the matrix (Figure 4A). In contrast, angiogenesis was inhibited in specimens cultured with 50 µg/ml of 7S domain (Figure 4B) and NC1 (Hexamer) domain (Figure 4C).

Figure 5 is a graphical representation of data demonstrating the in vivo effect of IV injection of recombinant ($\alpha 1$) type IV collagen monomer on angiogenesis using fibrin implants in rats.

Figure 6 is a graphical representation of data demonstrating that the recombinant ($\alpha 1$) and ($\alpha 2$) NC1 monomers inhibit the bFGF-induced increase in angiogenic index in vivo.

Figure 7 is a graphical representation of demonstrating the dose response effect of recombinant ($\alpha 2$) NC1 monomer on the bFGF-induced increase in total blood vessel branch points in vivo.

Figure 8 is a graphical representation of data demonstrating the dose response effect of recombinant ($\alpha 2$) NC1 monomer on the bFGF-induced increase in angiogenic index in vivo.

Figure 9 is a graphical representation of data demonstrating the dose response effect of recombinant ($\alpha 2$) NC1 monomer on the bFGF-induced increase in angiogenic index in vivo.

Figure 10 is a graphical representation of data demonstrating the effect of recombinant ($\alpha 1$) and ($\alpha 2$) NC1 monomers on mean CS-1 melanoma tumor weight in vivo.

Figure 11 is a graphical representation of data demonstrating the dose response effect of recombinant ($\alpha 2$) NC1 monomer on mean CS-1 melanoma tumor weight in vivo.

Figure 12 is a graphical representation of data demonstrating the effect of recombinant ($\alpha 1$), ($\alpha 2$), and ($\alpha 4$) NC1 monomers on mean HT1080 tumor weight in vivo.

Figure 13 is a graphical representation of data demonstrating the effect of recombinant ($\alpha 1$), ($\alpha 2$), ($\alpha 3$) and ($\alpha 5$) NC1 monomers on mean HEP-3 tumor weight in vivo.

Figure 14 is a graphical representation of data demonstrating human endothelial cell adhesion to immobilized NC1 α monomers.

5 **Figure 15** is a graphical representation of data demonstrating the effect of soluble $\alpha 1$ and $\alpha 2$ NC1 monomers on human endothelial cell adhesion to pepsinized collagen type IV.

Figure 16 is a graphical representation of data demonstrating the effect of isolated recombinant NC1 monomers on human endothelial cell migration in vitro.

Figure 17 A-F provides the sequences of each type IV collagen α chain monomer.

10

Description of the Preferred Embodiments

Within this application, unless otherwise stated, the techniques utilized may be found in any of several well-known references such as: *Molecular Cloning: A Laboratory Manual* (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), *Gene Expression Technology* (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991. Academic Press, San Diego, CA), "Guide to Protein Purification" in *Methods in Enzymology* (M.P. Deutscher, ed., (1990) Academic Press, Inc.); *PCR Protocols: A Guide to Methods and Applications* (Innis, et al. 1990. Academic Press, San Diego, CA), *Culture of Animal Cells: A Manual of Basic Technique, 2nd Ed.* (R.I. Freshney. 1987. Liss, Inc. New York, NY), and *Gene Transfer and Expression Protocols*, pp. 109-128, ed. E.J. Murray, The Humana Press Inc., Clifton, N.J.).

20 As used herein, the term Type IV collagen domain encompasses the group of molecules including the non-collagenous NC1 domain (Hexamer) and 7S collagenous domains, as well as NC1 α chain monomers.

The invention comprises methods for using Type IV collagen NCI α -monomers (ie: $\alpha 2$, $\alpha 3$, and $\alpha 6$), which are defined to include such monomers isolated from any multicellular organism or produced via recombinant protein expression from a gene encoding such a monomer from any multicellular organism, and also to encompass
 5 various modifications, additions, and /or deletions to such monomers.

In one aspect, the present invention provides methods and kits for inhibiting angiogenesis in an animal tissue comprising contacting the tumor or animal tissue with an amount effective to inhibit angiogenesis of a polypeptide composition comprising one or more isolated type IV collagen NCI α chain monomer selected from the group consisting
 10 of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NCI chain monomers.

In another aspect, the present invention provides methods and kits for inhibiting tumor growth in tissue comprising contacting the tumor or tissue with an amount effective to inhibit tumor growth of a polypeptide composition comprising one or more isolated type IV collagen NCI α chain monomer selected from the group consisting of $\alpha 2$, $\alpha 3$, and
 15 $\alpha 6$ chain monomers.

In another aspect, the present invention provides methods and kits for inhibiting tumor metastasis in tissue comprising contacting the tumor or tissue with an amount effective to inhibit metastasis of a polypeptide composition comprising one or more isolated type IV collagen NCI α chain monomer selected from the group consisting of $\alpha 2$,
 20 and $\alpha 6$ NCI chain monomers.

In a further aspect, the present invention provides methods and kits for inhibiting endothelial cell interactions with the extracellular matrix in tissue comprising contacting the tumor or tissue with an amount effective to inhibit endothelial cell interactions with the extracellular matrix of a polypeptide composition comprising one or more isolated
 25 type IV collagen NCI α chain monomer selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NCI chain monomers.

The NCI-encoding domain of each of the six α chain cDNAs has been cloned into a vector for recombinant protein expression as previously described (Sado et al., Kidney Intl. 53:664-671 (1998), incorporated by reference herein in its entirety). The vectors are
 30 used to stably transfect human kidney 293 cells, which produce the recombinant protein. The DNA and deduced amino acid sequences of the recombinant type IV collagen alpha chain monomers produced as described are shown in Figure 17A-F. The first 17 amino acids corresponds to a BM40 signal sequence (which is cleaved from the mature protein), to facilitate protein secretion. All the secreted proteins (ie: mature proteins) start with the sequence APLA followed by the affinity tag, DYKDDDDK at the amino terminus. This



tag facilitates purification and identification of the material, and does not interfere with biological activity of the recombinant NCI α chain monomer.

The type IV collagen NCI α chain monomers can be produced by any method known in the art, including using recombinant DNA technology or biochemical peptide
5 synthesis technology, or by isolating the NCI domains from animal sources, such as from basement membrane sources such as bovine lens capsule and bovine kidney glomeruli. (Peczon et al., Exp. Eye Res. 30:155-165 (1980); Langeveld et al., J. Biol. Chem. 263:10481-10488 (1988); Gunwar et al., J. Biol. Chem. 266:14088-14094 (1991))

In practicing the invention, the amount or dosage range of type IV collagen NCI α
10 chain monomers employed is one that effectively inhibits angiogenesis, tumor growth, tumor metastasis, and/or endothelial cell-extracellular matrix interactions. An inhibiting

B
I
O
P
A
T
E
N
TS
E
R
I
E
S

amount of NC1 α chain monomers that can be employed ranges generally between about 0.01 $\mu\text{g/kg}$ body weight and about 10 mg/kg body weight, preferably ranging between about 0.05 $\mu\text{g/kg}$ and about 5 mg/kg body weight.

The NC1 α chain monomers may be administered by any suitable route, including
5 orally, parentally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. The term parenteral as used herein includes, subcutaneous, intravenous, intraarterial, intramuscular, intrasternal, intratendinous, intraspinal, intracranial, intrathoracic, infusion techniques or intraperitoneally. In preferred embodiments, the NC1 α chain monomers are
10 administered intravenously or subcutaneously.

The NC1 α chain monomers may be made up in a solid form (including granules, powders or suppositories) or in a liquid form (e.g., solutions, suspensions, or emulsions). The NC1 α chain monomers of the invention may be applied in a variety of solutions. Suitable solutions for use in accordance with the invention are sterile, dissolve sufficient
15 amounts of the NC1 α chain monomers, and are not harmful for the proposed application.

The NC1 α chain monomers may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc.

For administration, the NC1 α chain monomers are ordinarily combined with one
20 or more adjuvants appropriate for the indicated route of administration. The compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanolic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinylpyrrolidone,

and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration. Alternatively, the compounds of this invention may be dissolved in saline, water, polyethylene glycol, propylene glycol, carboxymethyl cellulose colloidal solutions, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, and/or various
5 buffers. Other adjuvants and modes of administration are well known in the pharmaceutical art. The carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials well known in the art.

The present invention may be better understood with reference to the
10 accompanying examples that are intended for purposes of illustration only and should not be construed to limit the scope of the invention, as defined by the claims appended hereto.

Example 1 – In Vitro Effect on Angiogenesis

With modifications, the procedures of Nicosia and Ottinetti (1990), *supra*, and
15 Nicosia, et. al. (1994), *supra*, were utilized for experiments designed to test the effect of Type IV collagen on angiogenesis under *in vitro* conditions. The model has been used to study the effects of growth factors and extracellular matrix molecules on the angiogenic response and employs aortic rings cultures in three-dimensional collagen gels under serum-free conditions. These experiments are outlined below.

A. Methods

Experiments were performed with 1-3 month old Swiss Webster male mice. Following anesthesia, the thoracic aorta was excised under aseptic conditions and transferred to sterile MCDB 131 sterile growth medium (Clonetics, San Diego, CA) containing antibiotics. Fat was dissected away from the aorta and approximately six to

eight 1 mm thoracic segments were obtained from each specimen. Segments were transferred to 48 well tissue culture plates. The wells of these plates were layered with 100 microliters of Matrigel (EHS basement membrane, Collaborative Biomedical Products, Bedford, MA) prior to transfer of the aortic segments. The Matrigel was diluted 1:1 with MCDB 131 growth medium prior to use. The segments were centered in the wells and an additional 100 microliters of Matrigel was then placed over the specimens. The aortic segments were therefore embedded in the basement membrane matrix. Each well then received 300 microliters of MCDB 131 growth medium. The plates were placed in an incubator maintained at 37° C with 5% CO₂. Specimens were observed daily over a 7 day period. Newly growing microvessels were counted using an inverted phase microscope at various times during the culture period, but data is expressed at 3 and 5 days of culture. To test for the effect of Type IV collagen on angiogenesis, domains at known concentrations were mixed with the Matrigel and with the MCDB 131 growth medium. Fresh MCDB 131 growth medium (plus and minus collagen domains) was changed every 3 days.

B. Results

After establishing the time course of angiogenesis under control conditions (Matrigel plus MCDB 131 growth medium), experiments were performed using various concentrations of Type IV collagen (isolated from bovine lens) NC1 (hexamer) and 7S domains. Data represents the analysis of at least 3 specimens per experimental condition. In the first experiment (**Figure 1**), analysis indicated that at a concentration of 50 µg/ml, NC1 domain and 7S domain significantly inhibited angiogenesis as monitored at 3 and 5 days of culture. In the second experiment, various concentrations of these domains were

analyzed. As indicated in **Figure 3**, 7S domain at 50 µg/ml again significantly inhibited angiogenesis at 3 and 5 days. Inhibition was reduced at 5 and 0.5 µg/ml concentrations. As indicated in **Figure 2**, NC1 domain was less effective in blocking angiogenesis as compared to that observed in the first experiment (**Figure 1**), although it was still
5 effective. In addition, as compared to the 7S domain, there was less of a correlation between concentration and inhibitory action.

Figure 4A-C are photographs of mouse thoracic aorta segments embedded in Matrigel (EHS basement membrane matrix, Collaborative Biomedical Products, Bedford, MA) at 5 days of culture in the presence or absence of 50 µg/ml of Type IV collagen
10 domains. The control specimen (no domains) exhibited growth of microvessels from the cultured tissue into the matrix (**Figure 4A**). In contrast, angiogenesis inhibition was observed in tissues cultured in the presence of 50 µg/ml of 7S (**Figure 4B**) and NC1 (Hexamer) domain (**Figure 4C**).

15 **Example 2. Subcutaneous fibrin implant angiogenesis**

Recombinant human type IV collagen NC1 (α3) monomer (Sado et al., Kidney International 53:664-671 (1998)) was injected intravenously in Fisher 344 rats containing fibrin implants surgically placed subcutaneously, a modified version of the method described by Dvorak et al (Lab. Invest. 57(6):673-686 (1987)). The implants were then
20 removed and directly analyzed using an inverted microscope. The analysis involved counting the number of blood vessels that had grown into the fibrin in the control and experimental group.

Briefly, 4 fibrin implants were surgically implanted subcutaneously into Fisher 344 rats (2 dorsal and 2 ventral sides). The average rat weight was approximately 125 grams.

Three rats (EXP) were given tail vein injections of either control (fibrin alone), 100 μ l of 100 μ g/ml of 7S domain of type IV collagen (approximately 0.80 mg/kg body weight), 100 μ l of 100 μ g/ml of type IV collagen hexamer (approximately 0.80 mg/kg body weight), or recombinant collagen type IV NC1 (α 3) monomer at a concentration of 1.26 mg/ml in PBS (120 μ g protein, or approximately 0.96 mg/kg body weight) and 3 rats (C) were given 100 μ l tail vein injections of PBS. Injections of recombinant protein were given every other day for five doses. The injection schedule was as follows:

Day 1: (implant day) injection and remove blood sample (EXP and C)
 Day 3: Injection (EXP and C)
 Day 5: Injection and remove blood sample (EXP and C)
 Day 7: Injection (EXP and C)
 Day 9: Injection and remove blood sample (EXP and C)
 Day 11: Remove and fix implants (save blood sample) (EXP and C)

The results of one experiment were as follows:

2 week in vivo experiment:

Control (fibrin alone)	about 66 BV
7S domain of type IV lens collagen (100 μ g/ml)	None
Hexamer of type IV lens collagen (100 μ g/ml)	None
Monomer (α 3)	None

The results are shown as the mean number of blood vessels per implant. The results of this study demonstrate that isolated domains of type IV collagen, including the α 3 monomer, can significantly inhibit capillary growth in the in vivo fibrin clot implant model. In subsequent experiments, the inhibitory effect was occasionally seen to attenuate with time, suggesting that higher dosages or more frequent injections might be even more effective.

A similar experiment was conducted using recombinant human type IV collagen NC1 (α 1) monomer (100 μ l of a 1 μ g/ μ l solution; approximately 0.80 mg/kg body weight)

and comparing the number of blood vessels that had grown into the fibrin at day 11 of treatment relative to the control group. Three rats per group were analyzed with each rat having 4 implants. These experiments demonstrated that administration of the $\alpha 1$ monomer significantly inhibited capillary growth in the in vivo fibrin clot implant model
5 (Figure 5).

Example 3. Recombinant NC1 ($\alpha 2$) domain inhibits angiogenesis in vivo

We next tested the effects of systemic administration of soluble NC1 α -chain
10 monomers in the chick embryo CAM angiogenesis assay.

Angiogenesis was induced in the CAMs of 10 day old chick embryos with bFGF as described (Brooks et al., Cell 92:391-400 (1998)). Twenty four hours later the embryos were systemically treated with various concentrations of recombinant NC1 α -chain monomers, in a total volume of 100 μ l of sterile phosphate buffered saline (PBS). Two
15 days later the embryos were sacrificed and the filter discs and CAM tissues removed. Angiogenesis was quantitated by counting the number of angigogenic blood vessel branch points in the confined area of the filter disc. The Angiogenic Index is defined as the number of branch points from experimental treatment minus control treatment.

In initial experiments, recombinant $\alpha 1$ or $\alpha 2$ NC1 domains were injected at a
20 concentration of 50 μ g per embryo. At this concentration, the NC1 domains were shown to be highly toxic as demonstrated by greater than 90% embryo cell death. However, at lower doses they were well tolerated and showed potent anti-angiogenic activity. A total of 6 individual angiogenesis experiments were conducted with the NC1 domains. However, in two experiments, the bFGF induction was low, making it difficult to interpret

the results. The NC1 $\alpha 2$ domain appeared to be more consistent and potent than the $\alpha 1$ NC1 domain at inhibiting angiogenesis. In fact, systemic administration of 30 μ g of NC1 $\alpha 2$ consistently inhibited angiogenesis by greater than 90% (**Figures 6-9**), as measured by inhibition of the bFGF-induced increase in the angiogenic index and the mean number of blood vessel branch points. In contrast, NC1 $\alpha 1$ domain showed variable inhibitory activity (0%-50%) throughout the experiments.

Example 4. Recombinant NC1 domain inhibits melanoma tumor growth in vivo:

Since the growth of all solid tumors depends on angiogenesis to provide nutrients for its continued expansion, reagents that have the capacity to inhibit angiogenesis may significantly inhibit tumor growth. Therefore, we tested the effects of recombinant NC1 domains of type IV collagen for their effects on tumor growth in vivo.

To test the effects of NC1 domains on tumor growth in vivo, we utilized the chick embryo tumor growth assay. Briefly, single cell suspensions of 3 distinct tumor types were applied to the CAM of 10 day old chick embryos. The tumors included CS-1 Melanoma cells (5×10^6), HT1080 human fibrosarcoma cells (4×10^5) and Hep-3 human epidermoid carcinoma cells (2×10^5). The embryos were injected systemically with varying concentrations of NC1 α -chain monomers 24 hours later. The embryos were next allowed to incubate for a total of 7 days, at which time they were sacrificed. The resulting tumors were resected and wet weights determined. A total of 6 tumor growth assays were conducted with the 3 distinct tumor types. A single injection of 10 μ g NC1 $\alpha 2$ domain inhibited CS1 melanoma tumor growth by approximately 70% relative to control (**Figure 10**). In similar experiments, dose response curves were completed with CS-1 tumors.

Systemic administration of NC1 α 2 resulted in a dose-dependent inhibition of CS-1 melanoma tumor growth in vivo with a maximum inhibition following a single dose at 30 μ g (**Figure 11**). Systemic administration of NC1 α 1 also inhibited CS-1 tumor growth but it was variable and in some experiments failed to inhibit tumor growth (**See Figure 10**).

- 5 In similar experiments, NC1 α 2 inhibited HT1080 human fibrosarcoma tumor growth by approximately 50% after a single systemic injection of 30 μ g, while NC1 α 1 and α 4 had no effect (**Figure 12**). Finally, systemic administration of NC1 α 2 (30.0 μ g) and α 3 inhibited Hep-3 human epidermoid carcinoma tumor growth by approximately 40% and 60% respectively, and α 1 inhibited Hep-3 tumor growth by approximately 30%, while
10 NC1 α 5 domain failed to inhibit tumor growth (**Figure 13**).

We conclude from these in vivo studies that tumor growth can be inhibited by isolated NC1 α -chain monomers. These molecules can thus be used alone, or to complement the use of existing anti-tumor agents, in providing enhanced and more effective anti-tumor therapy.

15

Example 5. Immobilized NC1 domains support human endothelial cell adhesion

In order for new blood vessels to form, endothelial cells must have the capacity to adhere and migrate through the ECM. Moreover, this endothelial cell-ECM interaction may facilitate signal transduction events required for new blood vessel formation.
20 Therefore, since type IV-collagen is an ECM protein which is known to support cell adhesion, we tested the ability of the NC1 domains to support endothelial cell attachment.

Microtiter plates were coated with 25 μ g/ml of purified NC1 domains followed by incubation with 1% bovine serum albumin (BSA) to block non-specific interactions.

Human endothelial cells (ECV304) were then allowed to attach to the immobilized NC1 domains for 1 hour. Non-adherent cells were removed by washing and attached cells were quantified by measuring the optical density (O.D.) of crystal violet eluted from attached cells. Data bars represent the mean $\pm$ standard error of the O.D. from triplicate wells.

5 Immobilized NC1 α 2, α 3, and α 6 domains supported endothelial cell adhesion while NC1 α 1, α 4, and α 5 domains promoted little if any cell adhesion (**Figure 14**). Soluble NC1 α 1 (α 1) and α 2 (α 2) inhibited endothelial cell adhesion to pepsinized collagen type IV by approximately 50% (**Figure 15**).

10 Taken together, these findings demonstrate that isolated, recombinant NC1 domains from the α 1, α 2, α 3, and α 6 chains of collagen type IV can mediate human endothelial cell adhesion and/or inhibit endothelial cell adhesion to ECM proteins in vitro, and suggest that the potent anti-angiogenic and anti-tumor activity of the isolated NC1 domains is due to disruption of endothelial cell interaction with the extracellular matrix that are necessary for angiogenesis.

15

Example 6. Endothelial Cell Migration

Invasive cellular processes such as angiogenesis and tumor metastasis also require cellular motility. Thus we evaluated the ability of isolated NC1 domains to support human endothelial cell migration in vitro. These experiments were conducted essentially
20 according to the methods in Brooks et al., J. Clin. Invest. 99:1390-1398 (1997).

The results of these experiments indicate that NC1 α 2, α 3, and α 6 domains can support human endothelial cell migration in vitro, while α 1, α 4, and α 5 domains showed little if any capacity to support endothelial cell migration (**FIG 16**).

Example 7. Efficacy in Lewis lung in vivo tumor

The above studies indicated that specific domains of collagen type IV can promote cell migration in vitro. Thus, we evaluated the ability of NC1 domains to support
5 endothelial cell migration in vivo.

The α (IV) NC1 domain hexamer, isolated by enzymatic digestion of bovine lens capsule basement membrane by known protocols (Peczon et al., Exp. Eye Res. 30:155-165 (1980)) was tested in the metastatic Lewis lung mouse tumor model using a standard protocol which is considered to be a good model of both metastasis and angiogenesis of
10 lung tumors. (See for example, Teicher et al., Anticancer Res. 18:2567-2573 (1998); Guibaud et al., Anticancer Drugs 8:276-282 (1997); Anderson et al., Cancer Res. 56:715-718 (1996)).

Each study consisted of an untreated control group and six treatment groups. There were ten animals per treatment group with 40 mice in the control. In each study, all
15 treatment was administered intravenously once every 2 days for 7 doses starting one day after tumor inoculation. Dosages of α (IV) NC1 hexamer were either 100 μ g/mouse or 200 μ g/mouse. In the Lewis lung study, the tumor cell inoculum was 1×10^6 viable cells. All animals were weighed twice a week throughout the study. Starting one day after the last treatment, 5 mice were periodically sacrificed from each control group to measure
20 pulmonary tumor burden. The experiment was terminated at day 14 when the lungs of the control animals had sufficient tumor mass to provide meaningful evaluation. At that time, the lungs of all remaining animals were excised, weighed, and the number of tumor foci greater than 2 mm in diameter counted. The resulting data showed that both dosages of α (IV) NC1 hexamer significantly reduced the number of visible lung metastases (Mann-

Whitney Rank Sum Test, $p < 0.05$), with 8 visible lung metastases in the control, vs. 5 (100 $\mu\text{g}/\text{mouse}$) and 4 (200 $\mu\text{g}/\text{mouse}$), and the 100 $\mu\text{g}/\text{mouse}$ dosage reduced the lung weights from a median of 520 mg in controls to a median of 462 mg in experimental, while the median lung weight of mice treated with 200 $\mu\text{g}/\text{mouse}$ was 620 mg.

5 Other in vivo studies demonstrated that tumor cell metastasis to the lung can be reduced by 50% or more using intravenous injections of the Type IV collagen domains in murine B16 melanoma, human A375SM melanoma xenografts. Furthermore, injection of the NC1 hexamer also significantly reduced the number of lung tumors in separate Lewis Lung tumor studies.

10

We conclude from all of the above studies that angiogenesis, tumor growth and metastasis, and endothelial cell adhesion to the ECM, can be inhibited by isolated, recombinant domains of type IV collagen. The present invention is thus broadly applicable to a variety of uses which include inhibition of angiogenesis and treatment of
15 diseases and conditions with accompanying undesired angiogenesis, such as solid and blood-borne tumors including but not limited to melanomas, carcinomas, sarcomas, rhabdomyosarcoma, retinoblastoma, Ewing sarcoma, neuroblastoma, osteosarcoma, and leukemia.

The invention is further applicable to treating non-tumorigenic diseases and
20 conditions with accompanying undesired angiogenesis, including but not limited to diabetic retinopathy, rheumatoid arthritis, retinal neovascularization, choroidal neovascularization, macular degeneration, corneal neovascularization, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, epidemic keratoconjunctivitis, Vitamin A deficiency, contact lens overwear, atopic

keratitis, superior limbic keratitis, pterygium keratitis sicca, sogrens, acne rosacea, phlyctenulosis, syphilis, Mycobacteria infections, lipid degeneration, chemical burns, bacterial ulcers, fungal ulcers, Herpes simplex infections, Herpes zoster infections, protozoan infections, Kaposi's sarcoma, Mooren ulcer, Terrien's marginal degeneration, 5 marginal keratolysis, traum, systemic lupus, polyarteritis, Wegeners sarcoidosis, scleritis, Steven's Johnson disease, radial keratotomy, sickle cell anemia, sarcoid, pseudoxanthoma elasticum, Pagets disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis, chronic vitritis, Lyme's disease, Eales disease, Bechets disease, myopia, optic pits, Stargarts disease, pars planitis, chronic retinal detachment, hyperviscosity 10 syndromes, toxoplasmosis, post-laser complications, abnormal proliferation of fibrovascular tissue, hemangiomas, Osler-Weber-Rendu, acquired immune deficiency syndrome, ocular neovascular disease, osteoarthritis, chronic inflammation, Crohn's disease, ulcerative colitis, psoriasis., atherosclerosis, and pemphigoid. See U.S. Patent No. 5,712,291)

15 The invention is also broadly applicable to methods for inhibiting tumor growth and metastasis, reduction of scar tissue formation, reduction of complications due to cell adhesion in organ transplants, and the inhibition of lymphocyte adhesion and mobility.

While the fundamental novel features of the invention have been shown and described, it will be understood that various omissions, substitutions, and changes in the 20 form and details illustrated may be made by those skilled in the art without departing from the spirit of the invention. For example, various modifications, additions. and/or substitutions can be made to the type IV collagen α monomer chains that would be encompassed by the invention. It is the intention, therefore, to be limited only as indicated by the scope of the following claims:

The claims defining the invention are as follows:

1. A method for inhibiting angiogenesis in an animal tissue comprising contacting the tumor or animal tissue with an amount effective to inhibit angiogenesis of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen
5 selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers.
2. A method for inhibiting tumor metastasis in tissue comprising contacting the tumor or tissue with an amount effective to inhibit tumor metastasis of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers.
- 10 3. A method for inhibiting tumor growth in tissue comprising contacting the tumor or tissue with an amount effective to inhibit tumor growth of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, and $\alpha 6$ NC1 chain monomers.
4. A kit when used for practicing the method of claim 1 comprising:
 - 15 a. an amount effective to inhibit angiogenesis in an animal tissue of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers, and
 - b. instructions for using the amount effective of isolated NC1 α chain monomers of type IV collagen to inhibit angiogenesis in an animal tissue.
- 20 5. A kit when used for practicing the method of claim 2 comprising:
 - a. an amount effective to inhibit tumor metastasis in tissue of an isolated domain of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers, and
 - 25 b. instructions for using the amount effective of isolated NC1 α chain monomers of type IV collagen to inhibit tumor metastasis in an animal tissue.
6. A kit when used for practicing the method of claim 3 comprising:
 - a. an amount effective to inhibit tumor growth in tissue of an isolated domain of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, and $\alpha 6$ NC1 chain monomers, and
 - 30 b. instructions for using the amount effective of isolated NC1 α chain monomers of type IV collagen to inhibit tumor growth in an animal tissue.



7. The method of claim 1 wherein the isolated NC1 α chain monomer of type IV collagen is the α 2 chain monomer.

8. The method of claim 1 wherein the isolated NC1 α chain monomer of type IV collagen is the α 3 chain monomer.

5 9. The method of claim 1 wherein the isolated NC1 α chain monomer of type IV collagen is the α 6 chain monomer.

10. The method of claim 2 wherein the isolated NC1 α chain monomer of type IV collagen is the α 2 chain monomer.

10 11. The method of claim 2 wherein the isolated NC1 α chain monomer of type IV collagen is the α 3 chain monomer.

12. The method of claim 2 wherein the isolated NC1 α chain monomer of type IV collagen is the α 6 chain monomer.

13. The method of claim 3 wherein the isolated NC1 α chain monomer of type IV collagen is the α 2 chain monomer.

15 14. The method of claim 3 wherein the isolated NC1 α chain monomer of type IV collagen is the α 6 chain monomer.

15. A method for inhibiting endothelial cell interaction with the extracellular matrix in an animal tissue comprising contacting the tumor or animal tissue with an amount effective to inhibit endothelial cell interaction with the extracellular matrix of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of α 2, α 3, and α 6 NC1 chain monomers.

16. A kit when used for practicing the method of claim 15 comprising:

25 a. an amount effective to inhibit endothelial cell interaction with the extracellular matrix in an animal tissue of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of α 2, α 3, and α 6 NC1 chain monomers, and

b. instructions for using the amount effective of isolated NC1 α chain monomers of type IV collagen to inhibit endothelial cell interaction with the extracellular matrix in an animal tissue.

30 17. The method of claim 15 wherein the isolated NC1 α chain monomer of type IV collagen is the α 2 chain monomer.

18. The method of claim 15 wherein the isolated NC1 α chain monomer of type IV collagen is the α 3 chain monomer.

19. The method of claim 15 wherein the isolated NC1 α chain monomer of type IV collagen is the α 6 chain monomer.



20. A method for treating an angiogenesis-mediated disease or condition in a mammal, comprising administering to a mammal with an angiogenesis-mediated disease or condition an amount effective to inhibit angiogenesis of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers.

21. The method of claim 20 wherein the isolated NC1 α chain monomer of type IV collagen comprises the $\alpha 2$ NC1 chain monomer.

22. The method of claim 20 wherein the isolated NC1 α chain monomer of type IV collagen comprises the $\alpha 3$ NC1 chain monomer.

23. The method of claim 20 wherein the isolated NC1 α chain monomer of type IV collagen comprises the $\alpha 6$ NC1 chain monomer.

24. The method of any one of claims 20 to 23 wherein the angiogenesis-mediated disease or condition is selected from the group consisting of solid and blood-borne tumors, diabetic retinopathy, rheumatoid arthritis, retinal neovascularization, choroidal neovascularization, macular degeneration, corneal neovascularization, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, epidemic keratoconjunctivitis, Vitamin A deficiency, contact lens overwear, atopic keratitis, superior limbic keratitis, pterygium keratitis sicca, soggrens, acne rosacea, phlyctenulosis, syphilis, Mycobacteria infections, lipid degeneration, chemical burns, bacterial ulcers, fungal ulcers, Herpes simplex infections, Herpes zoster infections, protozoan infections, Kaposi's sarcoma, Mooren ulcer, Terrien's marginal degeneration, marginal keratolysis, traum, systemic lupus, polyarteritis, Wegeners sarcoidosis, scleritis, Steven's Johnson disease, radial keratotomy, sickle cell anemia, sarcoid, pseudoxanthoma elasticum, Pagets disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis, chronic vitritis, Lyme's disease, Eales disease, Bechets disease, myopia, optic pits, Stargarts disease, pars planitis, chronic retinal detachment, hyperviscosity syndromes, toxoplasmosis, post-laser complications, abnormal proliferation of fibrovascular tissue, hemangiomas, Osler-Weber-Rendu, acquired immune deficiency syndrome, ocular neovascular disease, osteoarthritis, chronic inflammation, Crohn's disease, ulcerative colitis, psoriasis., atherosclerosis, and pemphigoid.

25. A polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers when used for inhibiting angiogenesis in an animal tissue.



26. A polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers when used for inhibiting tumor metastasis in tissue.

27. A polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, and $\alpha 6$ NC1 chain monomers when used for inhibiting tumor growth in tissue.

28. The polypeptide when used according to claim 25 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 2$ chain monomer.

29. The polypeptide when used according to claim 25 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 3$ chain monomer.

30. The polypeptide when used according to claim 25 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 6$ chain monomer.

31. The polypeptide when used according to claim 26 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 2$ chain monomer.

32. The polypeptide when used according to claim 26 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 3$ chain monomer.

33. The polypeptide when used according to claim 26 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 6$ chain monomer.

34. The polypeptide when used according to claim 27 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 2$ chain monomer.

35. The polypeptide when used according to claim 27 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 6$ chain monomer.

36. A polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers when used for inhibiting endothelial cell interaction with the extracellular matrix in an animal tissue.

37. The polypeptide when used according to claim 36 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 2$ chain monomer.

38. The polypeptide when used according to claim 36 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 3$ chain monomer.

39. The polypeptide when used according to claim 36 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 6$ chain monomer.

40. A polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1



chain monomers when used for treating an angiogenesis-mediated disease or condition in a mammal.

41. The polypeptide when used according to claim 40 wherein the isolated NC1 α chain monomer of type IV collagen comprises the $\alpha 2$ NC1 chain monomer.

5 42. The polypeptide when used according to claim 40 wherein the isolated NC1 α chain monomer of type IV collagen comprises the $\alpha 3$ NC1 chain monomer.

43. The polypeptide when used according to claim 40 wherein the isolated NC1 α chain monomer of type IV collagen comprises the $\alpha 6$ NC1 chain monomer.

44. The polypeptide when used according to any one of claims 40 to 43 wherein the
10 angiogenesis-mediated disease or condition is selected from the group consisting of solid and blood-borne tumors, diabetic retinopathy, rheumatoid arthritis, retinal neovascularization, choroidal neovascularization, macular degeneration, corneal neovascularization, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, epidemic keratoconjunctivitis, Vitamin A deficiency,
15 contact lens overwear, atopic keratitis, superior limbic keratitis, pterygium keratitis sicca, soggrens, acne rosacea, phlyctenulosis, syphilis, Mycobacteria infections, lipid degeneration, chemical burns, bacterial ulcers, fungal ulcers, Herpes simplex infections, Herpes zoster infections, protozoan infections, Kaposi's sarcoma, Mooren ulcer, Terrien's marginal degeneration, marginal keratolysis, traum, systemic lupus, polyarteritis,
20 Wegeners sarcoidosis, scleritis, Steven's Johnson disease, radial keratotomy, sickle cell anemia, sarcoid, pseudoxanthoma elasticum, Pagets disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis, chronic vitritis, Lyme's disease, Eales disease, Bechets disease, myopia, optic pits, Stargarts disease, pars planitis, chronic retinal detachment, hyperviscosity syndromes, toxoplasmosis, post-laser complications,
25 abnormal proliferation of fibrovascular tissue, hemangiomas, Osler-Weber-Rendu, acquired immune deficiency syndrome, ocular neovascular disease, osteoarthritis, chronic inflammation, Crohn's disease, ulcerative colitis, psoriasis, atherosclerosis, and pemphigoid.

45. Use of a polypeptide composition comprising one or more isolated NC1 α
30 chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers in the manufacture of a medicament for inhibiting angiogenesis in an animal tissue.

46. Use of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$



NC1 chain monomers in the manufacture of a medicament for inhibiting tumor metastasis in tissue.

47. Use of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, and $\alpha 6$ NC1 chain monomers in the manufacture of a medicament for inhibiting tumor growth in tissue.

48. The use according to claim 45 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 2$ chain monomer.

49. The use according to claim 45 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 3$ chain monomer.

50. The use according to claim 45 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 6$ chain monomer.

51. The use according to claim 46 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 2$ chain monomer.

52. The use according to claim 46 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 3$ chain monomer.

53. The use according to claim 46 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 6$ chain monomer.

54. The use according to claim 47 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 2$ chain monomer.

55. The use according to claim 47 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 6$ chain monomer.

56. Use of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers in the manufacture of a medicament for inhibiting endothelial cell interaction with the extracellular matrix in an animal tissue.

57. The use according to claim 56 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 2$ chain monomer.

58. The use according to claim 56 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 3$ chain monomer.

59. The use according to claim 36 wherein the isolated NC1 α chain monomer of type IV collagen is the $\alpha 6$ chain monomer.

60. Use of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$



NC1 chain monomers in the manufacture of medicament for treating an angiogenesis-mediated disease or condition in a mammal.

61. The use according to claim 60 wherein the isolated NC1 α chain monomer of type IV collagen comprises the $\alpha 2$ NC1 chain monomer.

5 62. The use according to claim 60 wherein the isolated NC1 α chain monomer of type IV collagen comprises the $\alpha 3$ NC1 chain monomer.

63. The use according to claim 60 wherein the isolated NC1 α chain monomer of type IV collagen comprises the $\alpha 6$ NC1 chain monomer.

64. The use according to any one of claims 60 to 63 wherein the angiogenesis-mediated disease or condition is selected from the group consisting of solid and blood-borne tumors, diabetic retinopathy, rheumatoid arthritis, retinal neovascularization, choroidal neovascularization, macular degeneration, corneal neovascularization, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, epidemic keratoconjunctivitis, Vitamin A deficiency, contact lens overwear, 10 atopic keratitis, superior limbic keratitis, pterygium keratitis sicca, sogrens, acne rosacea, phlyctenulosis, syphilis, Mycobacteria infections, lipid degeneration, chemical burns, bacterial ulcers, fungal ulcers, Herpes simplex infections, Herpes zoster infections, protozoan infections, Kaposi's sarcoma, Mooren ulcer, Terrien's marginal degeneration, marginal keratolysis, traum, systemic lupus, polyarteritis, Wegeners sarcoidosis, scleritis, 15 Steven's Johnson disease, radial keratotomy, sickle cell anemia, sarcoid, pseudoxanthoma elasticum, Pagets disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis, chronic vitritis, Lyme's disease, Eales disease, Bechets disease, myopia, optic pits, Stargarts disease, pars planitis, chronic retinal detachment, hyperviscosity syndromes, toxoplasmosis, post-laser complications, abnormal proliferation of 20 fibrovascular tissue, hemangiomas, Osler-Weber-Rendu, acquired immune deficiency syndrome, ocular neovascular disease, osteoarthritis, chronic inflammation, Crohn's disease, ulcerative colitis, psoriasis., atherosclerosis, and pemphigoid.

65. A method for inhibiting angiogenesis in an animal tissue comprising contacting the tumor or animal tissue with an amount effective to inhibit angiogenesis of a polypeptide 30 composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers, said polypeptide composition being substantially as hereinbefore described with reference to any one of the examples and/or any one of the accompanying drawings, but excluding any comparative examples therein.



66. A method for inhibiting tumor metastasis in tissue comprising contacting the tumor or tissue with an amount effective to inhibit tumor metastasis of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers, said
 5 polypeptide composition being substantially as hereinbefore described with reference to any one of the examples and/or any one of the accompanying drawings, but excluding any comparative examples therein.

67. A method for inhibiting tumor growth in tissue comprising contacting the tumor or tissue with an amount effective to inhibit tumor growth of a polypeptide
 10 composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, and $\alpha 6$ NC1 chain monomers, said polypeptide composition being substantially as hereinbefore described with reference to any one of the examples and/or any one of the accompanying drawings, but excluding any comparative examples therein.

15 68. A method for inhibiting endothelial cell interaction with the extracellular matrix in an animal tissue comprising contacting the tumor or animal tissue with an amount effective to inhibit endothelial cell interaction with the extracellular matrix of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers, said
 20 polypeptide composition being substantially as hereinbefore described with reference to any one of the examples and/or any one of the accompanying drawings, but excluding any comparative examples therein.

69. A method for treating an angiogenesis-mediated disease or condition in a mammal, comprising administering to a mammal with an angiogenesis-mediated disease
 25 or condition an amount effective to inhibit angiogenesis of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers, said polypeptide composition being substantially as hereinbefore described with reference to any one of the examples and/or any one of the accompanying drawings, but excluding any comparative examples
 30 therein.

70. A polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers when used for inhibiting angiogenesis in an animal tissue, said polypeptide composition being substantially as hereinbefore described with reference to any



one of the examples and/or any one of the accompanying drawings, but excluding any comparative examples therein.

71. A polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers when used for inhibiting tumor metastasis in tissue, said polypeptide composition being substantially as hereinbefore described with reference to any one of the examples and/or any one of the accompanying drawings, but excluding any comparative examples therein.

72. A polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, and $\alpha 6$ NC1 chain monomers when used for inhibiting tumor growth in tissue, said polypeptide composition being substantially as hereinbefore described with reference to any one of the examples and/or any one of the accompanying drawings, but excluding any comparative examples therein.

73. A polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers when used for inhibiting endothelial cell interaction with the extracellular matrix in an animal tissue, said polypeptide composition being substantially as hereinbefore described with reference to any one of the examples and/or any one of the accompanying drawings, but excluding any comparative examples therein.

74. A polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers when used for treating an angiogenesis-mediated disease or condition in a mammal, said polypeptide composition being substantially as hereinbefore described with reference to any one of the examples and/or any one of the accompanying drawings, but excluding any comparative examples therein.

75. Use of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers in the manufacture of a medicament for inhibiting angiogenesis in an animal tissue, said polypeptide composition being substantially as hereinbefore described with reference to any one of the examples and/or any one of the accompanying drawings, but excluding any comparative examples therein.

76. Use of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers in the manufacture of a medicament for inhibiting tumor metastasis



in tissue, said polypeptide composition being substantially as hereinbefore described with reference to any one of the examples and/or any one of the accompanying drawings, but excluding any comparative examples therein.

77. Use of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, and $\alpha 6$ NC1 chain monomers in the manufacture of a medicament for inhibiting tumor growth in tissue, said polypeptide composition being substantially as hereinbefore described with reference to any one of the examples and/or any one of the accompanying drawings, but excluding any comparative examples therein.

78. Use of a polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers in the manufacture of a medicament for inhibiting endothelial cell interaction with the extracellular matrix in an animal tissue, said polypeptide composition being substantially as hereinbefore described with reference to any one of the examples and/or any one of the accompanying drawings, but excluding any comparative examples therein.

79. Use of polypeptide composition comprising one or more isolated NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers in the manufacture of a medicament for treating an angiogenesis-mediated disease or condition in a mammal, said polypeptide composition being substantially as hereinbefore described with reference to any one of the examples and/or any one of the accompanying drawings, but excluding any comparative examples therein.

Dated 27 March, 2002

University of Kansas Medical Center

Patent Attorneys for the Applicant/Nominated Person
SPRUSON & FERGUSON



1/28




FIG. 1

2/28




FIG. 2

3/28






FIG. 3

4/28



CONTROL
FIG. 4a



7S DOMAIN (50µg/ml)
FIG. 4b



NC1 DOMAIN (50µg/ml)
FIG. 4c

5/28




FIG. 5

6/28




FIG. 6

7/28




FIG. 7

8/28




FIG. 8

9/28




FIG. 9

10/28




FIG. 10

11/28




FIG. 11

12/28




FIG. 12

13/28




FIG. 13

14/28




FIG. 14

15/28




FIG. 15

16/28




FIG. 16

A. $\alpha 1$ (IV)NC1

17/28

```
900      910      920      930      940      950
|         |         |         |         |         |
CTGCCGCCTGCCTGCCACTGAGGGTTCCCAGCACCATGAGGGCCTGGATCTTCTTT
                                     M R A W I F F

960      970      980      990      1000     1010
|         |         |         |         |         |
CTCCTTTGCCTGGCCGGGAGGGCTCTGGCAGCCCCACTAGCCGACTACAAGGACGACGAT
L L C L A G R A L A A P L A D Y K D D D

1020     1030     1040     1050     1060     1070
|         |         |         |         |         |
GACAAGCTAGCATCTGTTGATCACGGCTTCCTTGTGACCAGGCATAGTCAAACAATAGAT
D K L A S V D H G F L V T R H S Q T I D

1080     1090     1100     1110     1120     1130
|         |         |         |         |         |
GACCCACAGTGTCCCTTCTGGGACCAAAATCTTTACCACGGGTACTCTTTGCTCTACGTG
D P Q C P S G T K I L Y H G Y S L L Y V

1140     1150     1160     1170     1180     1190
|         |         |         |         |         |
CAAGGCAATGAACGGGCCCATGGCCAGGACTTGGGCACGGCCGGCAGCTGCCTGCGCAAG
Q G N E R A H G Q D L G T A G S C L R K

1200     1210     1220     1230     1240     1250
|         |         |         |         |         |
TTCAGCACAAATGCCCTTCTGTTCTGCAATATTAACAACGTGTGCAACTTTGCATCACGA
F S T M P F L F C N I N N V C N F A S R

1260     1270     1280     1290     1300     1310
|         |         |         |         |         |
AATGACTACTCGTACTGGCTGTCCACCCCTGAGCCCATGCCCATGTCAATGGCACCCATC
N D Y S Y W L S T P E P M P M S M A P I

1320     1330     1340     1350     1360     1370
|         |         |         |         |         |
ACGGGGGAAAACATAAGACCATTATTAGTAGGTGTGCTGTGTGTGAGGCGCCTGCCATG
T G E N I R P F I S R C A V C E A P A M

1380     1390     1400     1410     1420     1430
|         |         |         |         |         |
GTGATGGCCGTGCACAGCCAGACCATTACAGATCCCACCGTGCCCCAGCGGGTGGTCCTCG
V M A V H S Q T I Q I P P C P S G W S S

1440     1450     1460     1470     1480     1490
|         |         |         |         |         |
CTGTGGATCGGCTACTCTTTTGTGATGCACACCAGCGCTGGTGCAGAAGGCTCTGGCCAA
L W I G Y S F V M H T S A G A E G S G Q

1500     1510     1520     1530     1540     1550
|         |         |         |         |         |
GCCCTGGCGTCCCCCGGCTCCTGCCTGGAGGAGTTTAGAAGTGCGCCATTTCATCGAGTGT
```

FIG. 17a

18/28

A L A S P G S C L E E F R S A P F I E C

1560 1570 1580 1590 1600 1610
CACGGCCGTGGGACCTGCAATTACTACGCAAACGCTTACAGCTTTTGGCTCGCCACCATA
H G R G T C N Y Y A N A Y S F W L A T I

1620 1630 1640 1650 1660 1670
GAGAGGAGCGAGATGTTCAAGAAGCCTACGCCGTCCACCTTGAAGGCAGGGGAGCTGCCG
E R S E M F K K P T P S T L K A G E L R

1680 1690 1700 1710 1720 1730
ACGCACGTCAGCCGCTGCCAAGTCTGTATGAGAAGAACATAATGAAGCCTGACTCAGCTA
T H V S R C Q V C M R R T - -

1740 1750 1760 1770 1780 1790
CCGCGGGCCCTATTCTATAGTGTACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTG

FIG. 17a

19/28

B. $\alpha 2$ (IV) NC1

900 910 920 930 940 950
CTGCCGCCTGCCTGCCCTGCCACTGAGGGTTCCCAGCACCATGAGGGCCTGGATCTTCTTT
M R A W I F F

960 970 980 990 1000 1010
CTCCTTTGCCTGGCCGGGAGGGCTCTGGCAGCCCCACTAGCCGACTACAAGGACGACGAT
L L C L A G R A L A A P L A D Y K D D D

1020 1030 1040 1050 1060 1070
GACAAGCTAGCCGTGAGCATCGGCTACCTCCTGGTGAAGCACAGCCAGACGGACCAGGAG
D K L A V S I G Y L L V K H S Q T D Q E

1080 1090 1100 1110 1120 1130
CCCATGTGCCCGGTGGGCATGAACAACTCTGGAGTGGATACAGCCTGCTGTACTTCGAG
P M C P V G M N K L W S G Y S L L Y F E

1140 1150 1160 1170 1180 1190
GGCCAGGAGAAGGCGCACACCAGGACCTGGGGCTGGCGGGCTCCTGCCTGGCGCGTTTC
G Q E K A H N Q D L G L A G S C L A R F

1200 1210 1220 1230 1240 1250
AGCACCATGCCCTTCTGTACTGCAACCCTGGTGATGTCTGCTACTATGCCAGCCGGAAC
S T M P F L Y C N P G D V C Y Y A S R N

1260 1270 1280 1290 1300 1310
GACAAGTCCTACTGGCTCTCTACCACTGCGCCGCTGCCCATGATGCCCGTGGCCGAGGAC
D K S Y W L S T T A P L P M M P V A E D

1320 1330 1340 1350 1360 1370
GAGATCAAGCCCTACATCAGCCGCTGTTCTGTGTGTGAGGCCCCGGCCATCGCCATCGCG
E I K P Y I S R C S V C E A P A I A I A

1380 1390 1400 1410 1420 1430
GTCCACAGTCAGGATGTCTCCATCCCACACTGCCCAGCTGGGTGGCGGAGTTTGTGGATC
V H S Q D V S I P H C P A G W R S L W I

1440 1450 1460 1470 1480 1490
GGATATTCTTCTCATGCACAGCGCGGGGAGACGAAGCGGTGGCCCAATCACTGGTG
G Y S F L M H T A A G D E G G G Q S L V

1500 1510 1520 1530 1540 1550

FIG. 17b

SUBSTITUTE SHEET (RULE 26)

20/28

```
| | | | | | | | | | | | | | | | | | | | | |
TCACCGGGCAGCTGTCTAGAGGACTTCCGCGCCACACCATTTCGAATGCAATGGAGGC
S P G S C L E D F R A T P F I E C N G G

1560      1570      1580      1590      1600      1610
| | | | | | | | | | | | | | | | | | | | | |
CGCGGCACCTGCCACTACTACGCCAACAAGTACAGCTTCTGGCTGACCACCATTCCCGAG
R G T C H Y Y A N K Y S F W L T T I P E

1620      1630      1640      1650      1660      1670
| | | | | | | | | | | | | | | | | | | | | |
CAGAGCTTCCAGGGCTCGCCCTCCGCGACACGCTCAAGGCCGGCCTCATCCGCACACAC
Q S F Q G S P S A D T L K A G L I R T H

1680      1690      1700      1710      1720      1730
| | | | | | | | | | | | | | | | | | | | | |
ATCAGCCGCTGCCAGGTGTGCATGAAGAACCTGTGAGCCGGCGGTGCCAGGGCCCTATT
I S R C Q V C M K N L -

1740      1750      1760      1770      1780      1790
| | | | | | | | | | | | | | | | | | | | | |
CTATAGTGTACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGC
```

FIG. 17b

SUBSTITUTE SHEET (RULE 26)

21/28

C. $\alpha 3$ (IV)NC1

900	910	920	930	940	950
CTGCCGCCTGCCTGCCTGCCACTGAGGGTCCAGCACCATGAGGGCCTGGATCTTCTTT					
M R A W I F F					
960	970	980	990	1000	1010
CTCCTTTGCCTGGCCGGGAGGGCTCTGGCAGCCCCGCTAGCCGACTACAAGGACGACGAT					
L L C L A G R A L A A P L A D Y K D D D					
1020	1030	1040	1050	1060	1070
GACAAACGTGGAGACAGTGGATCACCTGCAACCTGGACAACGAGAGGCTTTGTCTTCACC					
D K R G D S G S P A T W T T R G F V F T					
1080	1090	1100	1110	1120	1130
CGACACAGTCAAACACAGCAATTCCTTCATGTCCAGAGGGGACAGTGGCCACTCTACAGT					
R H S Q T T A I P S C P E G T V P L Y S					
1140	1150	1160	1170	1180	1190
GGGTTTCTTTCTTTTGTACAAGGAAATCAACGAGCCACGGACAAGACCTTGGAAC					
G F S F L F V Q G N Q R A H G Q D L G T					
1200	1210	1220	1230	1240	1250
CTTGGCAGCTGCCTGCAGCGATTACCACAAATGCCATTCTTATTCTGCAATGTCAATGAT					
L G S C L Q R F T T M P F L F C N V N D					
1260	1270	1280	1290	1300	1310
GTATGTAATTTTGCATCTCGAAATGATTATTCATACTGGCTGTCAACACCAGCTCTGATG					
V C N F A S R N D Y S Y W L S T P A L M					
1320	1330	1340	1350	1360	1370
CCAATGAACATGGCTCCCATTAAGTGGCAGAGCCCTTGAGCCTTATATAAGCAGATGCACT					
P M N M A P I T G R A L E P Y I S R C T					
1380	1390	1400	1410	1420	1430
GTTTGTGAAGGTCCTGCGATCGCCATAGCCGTTTACAGCCAAACCACTGACATTCCTCCA					
V C E G P A I A I A V H S Q T T D I P P					
1440	1450	1460	1470	1480	1490
TGTCTCACGGCTGGATTTCTCTGGAAAGGATTTTCATTCATCATGTTCAAGTGCA					
C P H G W I S L W K G F S F I M F T S A					
1500	1510	1520	1530	1540	1550

FIG. 17c

SUBSTITUTE SHEET (RULE 26)

22/28

```
|      |      |      |      |      |      |
GGTTCTGAGGGCGCCGGGCAAGCACTGGCCTCCCCCGGCTCCTGCCTGGAAGAATTCCGA
G S E G A G Q A L A S P G S C L E E F R

1560      1570      1580      1590      1600      1610
|      |      |      |      |      |
GCCAGCCCATTCTAGAATGTCATGGAAGAGGAACGTGCAACTACTATTCAAATTCCTAC
A S P F L E C H G R G T C N Y Y S N S Y

1620      1630      1640      1650      1660      1670
|      |      |      |      |      |
AGTTTCTGGCTGGCTTCATTAAACCCAGAAAGAATGTTTCAGAAAGCCTATTCCATCAACT
S F W L A S L N P E R M F R K P I P S T

1680      1690      1700      1710      1720      1730
|      |      |      |      |      |
GTGAAAGCTGGGGAATTAGAAAAAATAATAAGTCGCTGTCAGGTGTCATGAAGAAAAGA
V K A G E L E K I I S R C Q V C M K K R

1740      1750      1760      1770      1780      1790
|      |      |      |      |      |
CACTGAGGGCCCTATTCTATAGTGTACCTAAATGCTAGAGCTCGCTGATCAGCCTCGAC

H -
```

FIG. 17c

23/28

D. $\alpha 4$ (IV) NC1

900 910 920 930 940 950
CTGCCGCCTGCCTGCCACTGAGGGTTCCCAGCACCATGAGGGCCTGGATCTTCTTT
M R A W I F F

960 970 980 990 1000 1010
CTCCTTTGCCTGGCCGGGAGGGCTCTGGCAGCCCCGCTAGCCGACTACAAGGACGACGAT
L L C L A G R A L A A P L A D Y K D D D

1020 1030 1040 1050 1060 1070
GACAAGCCTGGATACCTCGGTGGCTTCTCCTGGTTCTCCACAGTCAGACGGACCAGGAG
D K P G Y L G G F L L V L H S Q T D Q E

1080 1090 1100 1110 1120 1130
CCCACCTGCCCCCTGGGCATGCCCAGGCTCTGGACTGGGTATAGTCTGTTATACCTGGAA
P T C P L G M P R L W T G Y S L L Y L E

1140 1150 1160 1170 1180 1190
GGGCAAGAGAAAGCTCACAATCAAGACCTTGGTCTGGCAGGGTCTTGCCTTCCCGTATTT
G Q E K A H N Q D L G L A G S C L P V F

1200 1210 1220 1230 1240 1250
AGCACGCTGCCCTTTGCCTACTGCAACATCCACCAGGTGTGCCACTATGCCCAGAGAAAC
S T L P F A Y C N I H Q V C H Y A Q R N

1260 1270 1280 1290 1300 1310
GACAGATCCTACTGGCTGGCCAGCGCTGCGCCCTCCCCATGATGCCACTCTCTGAAGAG
D R S Y W L A S A A P L P M M P L S E E

1320 1330 1340 1350 1360 1370
GCGATCCGCCCTATGTGACCGCTGTGCGGTATGCGAGGCCCCGGCCAGGCGGTGGCG
A I R P Y V S R C A V C E A P A Q A V A

1380 1390 1400 1410 1420 1430
GTGCACAGCCAGGACCAGTCCATCCCCCATGTCCGCAGACCTGGAGGAGCCTCTGGATC
V H S Q D Q S I P P C P Q T W R S L W I

1440 1450 1460 1470 1480 1490
GGGTATTCATTCTGATGCACACAGGAGCTGGGGACCAAGGAGGAGGGCAGGCCCTTATG
G Y S F L M H T G A G D Q G G G Q A L M

1500 1510 1520 1530 1540 1550

FIG. 17d

SUBSTITUTE SHEET (RULE 26)

24/28

```
| | | | | | | | | | | | | | | | | | | | | |
TCACCTGGCAGCTGCCTGGAAGATTTTCAGAGCAGCACCATTCTTGAATGCCAGGGCCGG
S P G S C L E D F R A A P F L E C Q G R

1560      1570      1580      1590      1600      1610
| | | | | | | | | | | | | | | | | | | | | |
CAGGGAACTTGCCACTTTTTCGCAAATAAGTATAGCTTCTGGCTCACAACGGTGAAAGCA
Q G T C H F F A N K Y S F W L T T V K A

1620      1630      1640      1650      1660      1670
| | | | | | | | | | | | | | | | | | | | | |
GACTTGCACTTTTCTCTGCTCCAGCACCAGACACCTTAAAGAAAGCCAGGCCCAACGC
D L Q F S S A P A P D T L K E S Q A Q R

1680      1690      1700      1710      1720      1730
| | | | | | | | | | | | | | | | | | | | | |
CAGAAAATCAGCCGGTGCCAGGTCTGCGTGAAGTATAGCTAGGGGCCCTATTCTATAGTG
Q K I S R C Q V C V K Y S -

1740      1750      1760      1770      1780      1790
| | | | | | | | | | | | | | | | | | | | | |
TCACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATC
```

FIG. 17d

SUBSTITUTE SHEET (RULE 26)

25/28

E. $\alpha 5$ (IV) NCI

900 910 920 930 940 950
CTGCCGCCTGCCTGCCACTGAGGGTTCCAGCACCATGAGGGCCTGGATCTTCTTT
M R A W I F F

960 970 980 990 1000 1010
CTCCTTTGCCTGGCCGGGAGGGCTCTGGCAGCCCCGCTAGCTGACTACAAGGACGACGAT
L L C L A G R A L A A P L A D Y K D D D

1020 1030 1040 1050 1060 1070
GACAAAGGTCCCCCTGGAACCTCCTCTGTGACATGGATTTCTTATTACAGCCACAGC
D K G P P G T S S V A H G F L I T R H S

1080 1090 1100 1110 1120 1130
CAGACAACGGATGCACCACAATGCCACAGGGAACACTTCAGGTCTATGAAGGCTTTTCT
Q T T D A P Q C P Q G T L Q V Y E G F S

1140 1150 1160 1170 1180 1190
CTCCTGTATGTACAAGGAAATAAAAGAGCCCACGGTCAAGACTTGGGGACGGCTGGCAGC
L L Y V Q G N K R A H G Q D L G T A G S

1200 1210 1220 1230 1240 1250
TGCCTTCGTCGCTTTAGTACCATGCCTTTTCATGTTCTGCAACATCAATAATGTTTGCAAC
C L R R F S T M P F M F C N I N N V C N

1260 1270 1280 1290 1300 1310
TTTGCTTCAAGAAATGACTATTCTTACTGGCTCTCTACCCCAGAGCCCATGCCAATGAGC
F A S R N D Y S Y W L S T P E P M P M S

1320 1330 1340 1350 1360 1370
ATGCAACCCCTAAAGGGCCAGAGCATCCAGCCATTCTAGTCGATGTGCAGTATGTGAA
M Q P L K G Q S I Q P F I S R C A V C E

1380 1390 1400 1410 1420 1430
GCTCCAGCTGTGGTGATCGCAGTTCACAGTCAGACGATCCAGATTCCTCCATTGTCTCTCAG
A P A V V I A V H S Q T I Q I P H C P Q

1440 1450 1460 1470 1480 1490
GGATGGGATTCTCTGTGGATTGGTTATTCCTTCATGATGCATACAAGTGCAGGGGCAGAA
G W D S L W I G Y S F M M H T S A G A E

1500 1510 1520 1530 1540 1550

FIG. 17e

SUBSTITUTE SHEET (RULE 26)

26/28

```

|   |   |   |   |   |   |
GGCTCAGGTCAAGCCCTAGCCTCCCTGGTTCCTGCTTGAAGAGTTTCGTTTCAGCTCCC
G S G Q A L A S P G S C L E E F R S A P

1560      1570      1580      1590      1600      1610
|   |   |   |   |   |   |
TTCATCGAATGTCATGGGAGGGGTACCTGTAAC TACTATGCCAACTCCTACAGCTTTTGG
F I E C H G R G T C N Y Y A N S Y S F W

1620      1630      1640      1650      1660      1670
|   |   |   |   |   |   |
CTGGCAACTGTAGATGTGTCTAGACATGTTCAAGTAAACCTCAGTCAGAAACGCTGAAAGCA
L A T V D V S D M F S K P Q S E T L K A

1680      1690      1700      1710      1720      1730
|   |   |   |   |   |   |
GGAGACTTGAGGACACGAATTAGCCGATGTCAAGTGTGCATGAAGAGGACATAACGCGGC
G D L R T R I S R C Q V C M K R T -

1740      1750      1760      1770      1780      1790
|   |   |   |   |   |   |
CGCTCGAGCATGCATCTAGAGGGCCCTATTCTATAGTGTACCTAAATGCTAGAGCTCGC

```

FIG. 17e

SUBSTITUTE SHEET (RULE 26)

27/28

F. $\alpha 6$ (IV) NC1

900 910 920 930 940 950
CTGCCGCCTGCCTGCCTGCCACTGAGGGTTCCCAGCACCATGAGGGCCTGGATCTTCTTT
M R A W I F F

960 970 980 990 1000 1010
CTCCTTTGCCTGGCCGGGAGGGCTCTGGCAGCCCCACTAGCCGACTACAAGGACGACGAT
L L C L A G R A L A A P L A D Y K D D D

1020 1030 1040 1050 1060 1070
GACAAGCTAGCGAGCATGAGAGTGGGCTACACGTTGGTAAAGCACAGCCAGTCGGAACAG
D K L A S M R V G Y T L V K H S Q S E Q

1080 1090 1100 1110 1120 1130
GTGCCCCGTGTCCCATCGGGATGAGCCAGCTGTGGGTGGGTACAGCTTACTGTTTGTG
V P P C P I G M S Q L W V G Y S L L F V

1140 1150 1160 1170 1180 1190
GAGGGGCAAGAGAAAGCCACAACCAGGACCTGGGCTTTGTGCTCCTGTCTGCCCCGC
E G Q E K A H N Q D L G F A G S C L P R

1200 1210 1220 1230 1240 1250
TTCAGCACCATGCCCTTCATCTACTGCAACATCAACGAGGTGTGCCACTATGCCAGGCGC
F S T M P F I Y C N I N E V C H Y A R R

1260 1270 1280 1290 1300 1310
AATGATAAATCTTACTGGCTCTCCACTACCGCCCTATCCCCATGATGCCCGTCAGCCAG
N D K S Y W L S T T A P I P M M P V S Q

1320 1330 1340 1350 1360 1370
ACCCAGATTCCCCAGTACATCAGCCGCTGCTCTGTGTGTGAGGCACCCCTCGCAAGCCATT
T Q I P Q Y I S R C S V C E A P S Q A I

1380 1390 1400 1410 1420 1430
GCTGTGCACAGCCAGGACATCACCATCCCGCAGTCCCCCTGGGCTGGCGCAGCCTCTGG
A V H S Q D I T I P Q C P L G W R S L W

1440 1450 1460 1470 1480 1490
ATTGGGTACTCTTTCTCATGCACACTGCCGCTGGTCCCGAGGGTGGAGGCCAGTCCCTG
I G Y S F L M H T A A G A E G G G Q S L

1500 1510 1520 1530 1540 1550

FIG. 17f

28/28

GTCTCACCTGGCTCCTGCCTAGAGGACTTTCGGGCCACTCCTTTCATCGAATGCAGTGGT
V S P G S C L E D F R A T P F I E C S G

1560 1570 1580 1590 1600 1610
GCCCCGAGGCACCTGCCACTACTTTGCAAACAAGTACAGTTTCTGGTTGACCACAGTGGAG
A R G T C H Y F A N K Y S F W L T T V E

1620 1630 1640 1650 1660 1670
GAGAGGCAGCAGTTTGGGGAGTTGCCTGTGTCTGAAACGCTGAAAGCTGGGCAGCTCCAC
E R Q Q F G E L P V S E T L K A G Q L H

1680 1690 1700 1710 1720 1730
ACTCGAGTCAGTCGCTGCCAGGTGTGTATGAAAAGCCTGTAGGGTGGCACCTGCCACGGG
T R V S R C Q V C M K S L -

1740 1750 1760 1770 1780 1790
CCCTATTCTATAGTGTACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTC

FIG. 17f